Niki BioSolutions (NIKI) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Niki BioSolutions (NIKI) has outperformed Tempest Therapeutics (TPST) over the past year, losing 82.1% versus a loss of 93.0%. Over five years, NIKI leads with a -98.3% price change compared with -99.6% for TPST. Niki BioSolutions is the larger company by market cap ($13.5 million vs $13.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NIKI | TPST |
|---|---|---|
| Share price | $4.32 | $0.77 |
| Market cap | $13.47M | $13.01M |
| 1-day change | -7.10% | -2.70% |
| YTD return | -59.25% | -73.17% |
| 1-year return | -82.07% | -92.99% |
| 5-year return | -98.33% | -99.60% |
| EPS (TTM) | $-2.90 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.00 | $12.23 |
| 52-week low | $4.10 | $0.743 |
| Distance from 52-week high | -82.00% | -93.70% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +809.09% |
| Average volume | 157.52K | 2.60M |
| Shares outstanding | 2.94M | 16.89M |
| Employees | 1 | 4 |
| Sector | Industrials | Health Care |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NIKI has outperformed TPST by 10.9 percentage points over the past year.
- The two companies sit in different sectors: Niki BioSolutions in Industrials and Tempest Therapeutics in Health Care.
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NIKI vs TPST FAQ
Which is bigger, Niki BioSolutions or Tempest Therapeutics?
Niki BioSolutions (NIKI) is larger, with a market capitalization of $13.47M compared with $13.01M for Tempest Therapeutics (TPST).
Which stock has performed better over the past year, NIKI or TPST?
NIKI returned -82.07% over the past 12 months, compared with -92.99% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Niki BioSolutions and Tempest Therapeutics in the same industry?
No. Niki BioSolutions is in the Industrials sector, while Tempest Therapeutics is in Health Care.